Cure Alzheimer's Fund Cure Alzheimer's Fund

G2T Research Models and Materials

2014 to 2024

Taconic Biosciences GMBH, a global provider of genetically modified mouse models and associated services, is providing customized mouse models (transgenic, conventional/conditional knock out, conventional/conditional knock in) for each specific gene and type of mutation that will be studied in the Genes to Therapies™ project.

Foundational Production of New Animal/Cellular Models of AD Taconic Biosciences

Funding to Date

$12,298,197

Focus

Foundational, Production of New Animal/Cellular Models of AD

Researchers

Taconic Biosciences

Related Content:


Plasma Proteins, Sex and Alzheimer’s Disease: Proteome-Wide Analyses of the UK Biobank and Framingham Heart Study P. Murali Doraiswamy 2024-12-16 Relationship Between Alzheimer’s Disease Risk Score and Outcomes of Mild Repetitive Neurotrauma Thomas McAllister Michael McCrea 2024-12-16 Alzheimer’s Disease PET Imaging of Nonfibrillar Amyloid Beta Aggregates Using Azapeptide (AZP) Tracer Sam Gandy Brigitte Guérin Shai Rahimipour William Lubell 2024-12-16 Investigating the Serial Pathologies Related to Plasma Biomarkers in NLFTaum/h Mice: A New Mouse Model Featuring Neurofibrillary Tangles as a Result of Rising Amyloid Beta without Microtubule-Associated Protein Tau (MAPT) Mutations Frances Edwards John Hardy 2024-12-16 Integrating Single-Cell Genomics for Pathways to Protection and Resilience Against Alzheimer’s Disease Winston Hide 2024-10-31 Midlife Autoantibody Profiles and the Risk of Late-Onset Alzheimer’s Disease in Women Yu Chen 2024-10-31 Mapping the X Chromosome Multi-Ome in Alzheimer’s and Parkinson’s Disease Michael Belloy 2024-09-17 Bioinformatics Platform for Modeling Alzheimer’s Progression (MAP-AD Platform) Ali Ezzati 2024-09-16